Abstract: A compound of the formula: or a pharmaceutically acceptable salt thereof,wherein Y is a direct link, --(CH.sub.2 --, --(CH.sub.2).sub.2 --, --CH.sub.2 O-- or CH.sub.2 S--; R is --CN or --CONH.sub.2 ;and R.sup.1 is a group of the formula: ##STR1## where R.sup.2 and R.sup.3 are each independently H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, --(CH.sub.2).sub.n OH, halo, trifluoromethyl, cyano, --(CH.sub.2).sub.n NR.sup.4 R.sup.5, --CO(C.sub.1 -C.sub.4 alkyl), --OCO(C.sub.1 -C.sub.4 alkyl), --CH(OH) (C.sub.1 -C.sub.4 alkyl), --C(OH) (C.sub.1 -C.sub.4 alkyl).sub.2, --SO.sub.2 NH.sub.2, --(CH.sub.2).sub.n CONR.sup.4 R.sup.5 or --(CH.sub.2).sub.n COO(C.sub.1 -C.sub.4 alkyl; R.sub.4 and R.sup.5 are each independently H or C.sub.1 -C.sub.4 alkyl; n is 0, 1 or 2;and "Het" is pyridyl, pyrazinyl or thienyl.The compounds are muscarinic receptor antagonists usedful in the treatment of diseases associated with the altered motility and/or tone of smooth muscle, especially irritable bowel syndrome.

Abstract: Compounds of formula (I): ##STR1## and pharmaceutically acceptable salt and biolabile esters thereof, wherein R.sup.1 is H, C.sub.1 -C.sub.4 alkyl, phenyl optionally substituted by up to three substituents independently selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen and CF.sub.3, or is 1-imidazolyl, 3-pyridyl or 4-pyridyl; R.sup.2 is H or C.sub.1 -C.sub.4 alkyl, R.sup.3 is SO.sub.2 R.sup.4 or COR.sup.4 where R.sup.4 is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.3 perfluoroalkyl(CH.sub.2).sub.p, C.sub.3 -C.sub.6 cycloalkyl(CH.sub.2).sub.p, aryl(CH.sub.2).sub.p, or heteroaryl(CH.sub.2).sub.p, p being 0, 1 or 2, or R.sup.4 may be NR.sup.5 R.sup.6 where R.sup.5 is H or C.sub.1 -C.sub.4 alkyl and R.sup.6 is C.sub.1 -C.sub.6, alkyl, C.sub.3 -C.sub.6 cycloalkyl or aryl, or R.sup.5 and R.sup.

Abstract: Compounds of the formulae: ##SPC1##And the salts thereof with pharmaceutically acceptable cations wherein R.sup.1 is 3-trifluoromethyl, chloro, bromo or fluoro; n and m are each two or three; X is oxygen or sulphur; R.sup.2 and R.sup.3, when taken separately, are each hydrogen or alkyl having 1 to 4 carbon atoms; R.sup.2 and R.sup.3, when taken together, are alkylene having 2 to 4 carbon atoms; Y is methylene or a single bond; R.sup.4 and R.sup.5, when taken separately, are each hydrogen, hydroxy or alkoxy having 1 to 4 carbon atoms, and R.sup.4 and R.sup.5, when taken together, are oxo or alkylene dioxy having 2 to 4 carbon atoms, each oxygen atom in R.sup.4 and R.sup.5, when taken separately, and in R.sup.4 and R.sup.5, when taken together, being separated from the nitrogen atom of the heterocyclic ring by two or more carbon atoms, said compounds being cerebral vasodilators.

Abstract: Compounds of the formulae: ##SPC1##And the salts thereof with pharmaceutically acceptable cations wherein R.sup.1 is 3-trifluoromethyl, chloro, bromo or fluoro; n and m are each two or three; X is oxygen or sulphur; R.sup.2 and R.sup.3, when taken separately, are each hydrogen or alkyl having 1 to 4 carbon atoms; R.sup.2 and R.sup.3, when taken together, are alkylene having 2 to 4 carbon atoms; Y is methylene or a single bond; R.sup.4 and R.sup.5, when taken separately, are each hydrogen, hydroxy or alkoxy having 1 to 4 carbon atoms, and R.sup.4 and R.sup.5, when taken together, are oxo or alkylene dioxy having 2 to 4 carbon atoms, each oxygen atom in R.sup.4 and R.sup.5, when taken separately, and in R.sup.4 and R.sup.5, when taken together, being separated from the nitrogen atom of the heterocyclic ring by two or more carbon atoms, said compounds being cerebral vasodilators.

Abstract: Compounds of the formulae: ##SPC1##And the salts thereof with pharmaceutically acceptable cations wherein R.sup.1 is 3-trifluoromethyl, chloro, bromo or fluoro; n and m are each two or three; X is oxygen or sulphur; R.sup.2 and R.sup.3, when taken separately, are each hydrogen or alkyl having 1 to 4 carbon atoms; R.sup.2 and R.sup.3, when taken together, are alkylene having 2 to 4 carbon atoms; Y is methylene or a single bond; R.sup.4 and R.sup.5, when taken separately, are each hydrogen, hydroxy or alkoxy having 1 to 4 carbon atoms, and R.sup.4 and R.sup.5, when taken together, are oxo or alkylene dioxy having 2 to 4 carbon atoms, each oxygen atom in R.sup.4 and R.sup.5, when taken separately, and in R.sup.4 and R.sup.5, when taken together, being separated from the nitrogen atom of the heterocyclic ring by two or more carbon atoms, said compounds being cerebral vasodilators.

Abstract: Compounds of the formulae: ##SPC1##And ##SPC2##And the salts thereof with pharmaceutically acceptable cations wherein R.sup.1 is 3-trifluoromethyl, chloro, bromo or fluoro; n and m are each two or three; X is oxygen or sulphur; R.sup.2 and R.sup.3, when taken separately, are each hydrogen or alkyl having 1 to 4 carbon atoms; R.sup.2 and R.sup.3, when taken together, are alkylene having 2 to 4 carbon atoms; Y is methylene or a single bond; R.sup.4 and R.sup.5, when taken separately, are each hydrogen, hydroxy or alkoxy having 1 to 4 carbon atoms, and R.sup.4 and R.sup.5, when taken together, are oxo or alkylene dioxy having 2 to 4 carbon atoms, each oxygen atom in R.sup.4 and R.sup.5, when taken separately, and in R.sup.4 and R.sup.5, when taken together, being separated from the nitrogen atom of the heterocyclic ring by two or more carbon atoms, said compounds being cerebral vasodilators.

Abstract: Compounds of the formulae: ##SPC1##And the salts thereof with pharmaceutically acceptable cations wherein R.sup.1 is 3-trifluoromethyl, chloro, bromo or fluoro; n and m are each two or three; X is oxygen or sulphur; R.sup.2 and R.sup.3, when taken separately, are each hydrogen or alkyl having 1 to 4 carbon atoms; R.sup.2 and R.sup.3, when taken together, are alkylene having 2 to 4 carbon atoms; Y is methylene or a single bond; R.sup.4 and R.sup.5, when taken separately, are each hydrogen, hydroxy or alkoxy having 1 to 4 carbon atoms, and R.sup.4 and R.sup.5, when taken together, are oxo or alkylene dioxy having 2 to 4 carbon atoms, each oxygen atom in R.sup.4 and R.sup.5, when taken separately, and in R.sup.4 and R.sup.5, when taken together, being separated from the nitrogen atom of the heterocyclic ring by two or more carbon atoms, said compounds being cerebral vasodilators.